## Philippe Lambin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1418477/publications.pdf

Version: 2024-02-01

495 46,459 94 192 g-index

512 512 512 512 34839

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours. Cancer Gene Therapy, 2022, 29, 178-188.	2.2	9
2	Development of a Management Algorithm for Acute and Chronic Radiation Urethritis and Cystitis. Urologia Internationalis, 2022, 106, 63-74.	0.6	8
3	A review in radiomics: Making personalized medicine a reality via routine imaging. Medicinal Research Reviews, 2022, 42, 426-440.	5.0	103
4	Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 – 2021. Expert Opinion on Therapeutic Patents, 2022, 32, 1-12.	2.4	14
5	Quality of life among patients with 4 to 10 brain metastases after treatment with whole-brain radiotherapy vs. stereotactic radiotherapy: a phase III, randomized, Dutch multicenter trial. Annals of Palliative Medicine, 2022, 11, 1197-1209.	0.5	2
6	A fully automatic artificial intelligence–based CT image analysis system for accurate detection, diagnosis, and quantitative severity evaluation of pulmonary tuberculosis. European Radiology, 2022, 32, 2188-2199.	2.3	30
7	A non-invasive, automated diagnosis of Menière's disease using radiomics and machine learning on conventional magnetic resonance imaging: A multicentric, case-controlled feasibility study. Radiologia Medica, 2022, 127, 72-82.	4.7	19
8	Transparency of deep neural networks for medical image analysis: A review of interpretability methods. Computers in Biology and Medicine, 2022, 140, 105111.	3.9	131
9	Improving and Externally Validating Mortality Prediction Models for COVID-19 Using Publicly Available Data. BioMed, 2022, 2, 13-26.	0.6	3
10	Deep Learning–based Automatic Lung Segmentation on Multiresolution CT Scans from Healthy and Fibrotic Lungs in Mice. Radiology: Artificial Intelligence, 2022, 4, e210095.	3.0	6
11	Data harmonisation for information fusion in digital healthcare: A state-of-the-art systematic review, meta-analysis and future research directions. Information Fusion, 2022, 82, 99-122.	11.7	62
12	A Handcrafted Radiomics-Based Model for the Diagnosis of Usual Interstitial Pneumonia in Patients with Idiopathic Pulmonary Fibrosis. Journal of Personalized Medicine, 2022, 12, 373.	1.1	6
13	CT Reconstruction Kernels and the Effect of Pre- and Post-Processing on the Reproducibility of Handcrafted Radiomic Features. Journal of Personalized Medicine, 2022, 12, 553.	1.1	4
14	MaasPenn Radiomics Reproducibility Score: A Novel Quantitative Measure for Evaluating the Reproducibility of CT-Based Handcrafted Radiomic Features. Cancers, 2022, 14, 1599.	1.7	4
15	An externally validated fully automated deep learning algorithm to classify COVID-19 and other pneumonias on chest computed tomography. ERJ Open Research, 2022, 8, 00579-2021.	1.1	6
16	Beyond automatic medical image segmentationâ€"the spectrum between fully manual and fully automatic delineation. Physics in Medicine and Biology, 2022, 67, 12TR01.	1.6	9
17	Automated detection and segmentation of non-small cell lung cancer computed tomography images. Nature Communications, 2022, $13$ , .	5.8	44
18	Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4452-4463.	3.3	29

#	Article	IF	Citations
19	Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. Autophagy, 2021, 17, 2604-2612.	4.3	59
20	The growing significance of smartphone apps in data-driven clinical decision-making: Challenges and pitfalls., 2021,, 173-182.		0
21	Artificial intelligence in oncology. , 2021, , 361-381.		4
22	Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1421-1430.	0.4	7
23	MRI-guided Radiation Therapy: An Emerging Paradigm in Adaptive Radiation Oncology. Radiology, 2021, 298, 248-260.	3.6	83
24	Lymph node response to chemoradiotherapy in oesophageal cancer patients: relationship with radiotherapy fields. Esophagus, 2021, 18, 100-110.	1.0	1
25	Cycle-Consistent Generative Adversarial Network: Effect on Radiation Dose Reduction and Image Quality Improvement in Ultralow-Dose CT for Evaluation of Pulmonary Tuberculosis. Korean Journal of Radiology, 2021, 22, 983.	1.5	9
26	Biomarkers for Hypoxia, HPVness, and Proliferation from Imaging Perspective., 2021,, 13-20.		0
27	A Dutch phase III randomized multicenter trial: whole brain radiotherapy versus stereotactic radiotherapy for 4–10 brain metastases. Neuro-Oncology Advances, 2021, 3, vdab021.	0.4	11
28	Radiomics: Transforming Standard Imaging into Mineable Data for Diagnostic and Theragnostic Applications. , 2021, , .		0
29	Prognostic and Predictive Value of Integrated Qualitative and Quantitative Magnetic Resonance Imaging Analysis in Glioblastoma. Cancers, 2021, 13, 722.	1.7	24
30	Deep learning for the fully automated segmentation of the inner ear on MRI. Scientific Reports, 2021, 11, 2885.	1.6	35
31	Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy. Cancers, 2021, 13, 1468.	1.7	24
32	Abstract IA-07: Radiomics: Transforming standard imaging into mineable data for diagnostic and theragnostic applications. , 2021, , .		0
33	[18F]FDG PET radiomics to predict disease-free survival in cervical cancer: a multi-scanner/center study with external validation. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3432-3443.	3.3	32
34	Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when combined with radiotherapy. , 2021, 9, e001764.		23
35	Structural and functional radiomics for lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3961-3974.	3.3	48
36	Can predicting COVID-19 mortality in a European cohort using only demographic and comorbidity data surpass age-based prediction: An externally validated study. PLoS ONE, 2021, 16, e0249920.	1.1	16

#	Article	IF	CITATIONS
37	Prognostic Assessment in High-Grade Soft-Tissue Sarcoma Patients: A Comparison of Semantic Image Analysis and Radiomics. Cancers, 2021, 13, 1929.	1.7	25
38	Knowledge Graphs for COVID-19: An Exploratory Review of the Current Landscape. Journal of Personalized Medicine, 2021, 11, 300.	1.1	18
39	The Effects of In-Plane Spatial Resolution on CT-Based Radiomic Features' Stability with and without ComBat Harmonization. Cancers, 2021, 13, 1848.	1.7	31
40	Limitations of Only Reporting the Odds Ratio in the Age of Precision Medicine: A Deterministic Simulation Study. Frontiers in Medicine, 2021, 8, 640854.	1.2	5
41	Modeling-Based Decision Support System for Radical Prostatectomy Versus External Beam Radiotherapy for Prostate Cancer Incorporating an In Silico Clinical Trial and a Cost–Utility Study. Cancers, 2021, 13, 2687.	1.7	1
42	The application of a workflow integrating the variable reproducibility and harmonizability of radiomic features on a phantom dataset. PLoS ONE, 2021, 16, e0251147.	1.1	25
43	Facile fabrication of lightweight porous FDM-Printed polyethylene/graphene nanocomposites with enhanced interfacial strength for electromagnetic interference shielding. Composites Science and Technology, 2021, 207, 108732.	3.8	49
44	MRI-Based Radiomics Analysis for the Pretreatment Prediction of Pathologic Complete Tumor Response to Neoadjuvant Systemic Therapy in Breast Cancer Patients: A Multicenter Study. Cancers, 2021, 13, 2447.	1.7	20
45	Development and External Validation of Deep-Learning-Based Tumor Grading Models in Soft-Tissue Sarcoma Patients Using MR Imaging. Cancers, 2021, 13, 2866.	1.7	24
46	A Prospectively Validated Prognostic Model for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Based on Radiomics of Computed Tomography Images. Cancers, 2021, 13, 3271.	1.7	12
47	Radiomics in Lung Diseases Imaging: State-of-the-Art for Clinicians. Journal of Personalized Medicine, 2021, 11, 602.	1.1	40
48	Efficient Secretion of Murine IL-2 From an Attenuated Strain of Clostridium sporogenes, a Novel Delivery Vehicle for Cancer Immunotherapy. Frontiers in Microbiology, 2021, 12, 669488.	1.5	10
49	Development and external validation of a non-invasive molecular status predictor of chromosome 1p/19q co-deletion based on MRI radiomics analysis of Low Grade Glioma patients. European Journal of Radiology, 2021, 139, 109678.	1.2	17
50	Reply to Orlhac, F.; Buvat, I. Comment on "lbrahim et al. The Effects of In-Plane Spatial Resolution on CT-Based Radiomic Features' Stability with and without ComBat Harmonization. Cancers 2021, 13, 1848― Cancers, 2021, 13, 3080.	1.7	7
51	An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication. Nature Cancer, 2021, 2, 709-722.	5.7	41
52	Deciphering the glioblastoma phenotype by computed tomography radiomics. Radiotherapy and Oncology, 2021, 160, 132-139.	0.3	9
53	Exploratory Radiomic Analysis of Conventional vs. Quantitative Brain MRI: Toward Automatic Diagnosis of Early Multiple Sclerosis. Frontiers in Neuroscience, 2021, 15, 679941.	1.4	7
54	Covid19Risk.ai: An Open Source Repository and Online Calculator of Prediction Models for Early Diagnosis and Prognosis of Covid-19. BioMed, 2021, 1, 41-49.	0.6	3

#	Article	IF	Citations
55	Making Radiomics More Reproducible across Scanner and Imaging Protocol Variations: A Review of Harmonization Methods. Journal of Personalized Medicine, 2021, 11, 842.	1.1	72
56	Privacy preserving distributed learning classifiers – Sequential learning with small sets of data. Computers in Biology and Medicine, 2021, 136, 104716.	3.9	12
57	Reproducibility of CT-Based Hepatocellular Carcinoma Radiomic Features across Different Contrast Imaging Phases: A Proof of Concept on SORAMIC Trial Data. Cancers, 2021, 13, 4638.	1.7	8
58	MRI-based delta-radiomics predicts pathologic complete response in high-grade soft-tissue sarcoma patients treated with neoadjuvant therapy. Radiotherapy and Oncology, 2021, 164, 73-82.	0.3	35
59	Development and Validation of an Automated Radiomic CT Signature for Detecting COVID-19. Diagnostics, 2021, 11, 41.	1.3	31
60	Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506. Molecular Cancer Therapeutics, 2021, 20, 2372-2383.	1.9	17
61	Machine learning for grading and prognosis of esophageal dysplasia using mass spectrometry and histological imaging. Computers in Biology and Medicine, 2021, 138, 104918.	3.9	12
62	Design, synthesis, <i>inÂvitro</i> inhibition and toxicological evaluation of human carbonic anhydrases I, II and IX inhibitors in 5-nitroimidazole series. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 109-117.	2.5	20
63	Distributed learning on 20 000+ lung cancer patients – The Personal Health Train. Radiotherapy and Oncology, 2020, 144, 189-200.	0.3	97
64	Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial. Clinical and Translational Radiation Oncology, 2020, 21, 49-55.	0.9	11
65	Implementing Systems Modelling and Molecular Imaging to Predict the Efficacy of BCL-2 Inhibition in Colorectal Cancer Patient-Derived Xenograft Models. Cancers, 2020, 12, 2978.	1.7	8
66	Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape. PLoS Computational Biology, 2020, 16, e1008041.	1.5	13
67	Reply to "COVID-19 prediction models should adhere to methodological and reporting standards― European Respiratory Journal, 2020, 56, 2002918.	3.1	1
68	The "hype―of hydrops in classifying vestibular disorders: a narrative review. Journal of Neurology, 2020, 267, 197-211.	1.8	21
69	A novel co-culture assay to assess anti-tumor CD8+ T cell cytotoxicity via luminescence and multicolor flow cytometry. Journal of Immunological Methods, 2020, 487, 112899.	0.6	23
70	Blockchain for Privacy Preserving and Trustworthy Distributed Machine Learning in Multicentric Medical Imaging (C-DistriM). IEEE Access, 2020, 8, 183939-183951.	2.6	44
71	Diagnosis of Invasive Lung Adenocarcinoma Based on Chest CT Radiomic Features of Part-Solid Pulmonary Nodules: A Multicenter Study. Radiology, 2020, 297, 451-458.	3.6	64
72	<i>E. coli</i> nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications. Theranostics, 2020, 10, 10548-10562.	4.6	15

#	Article	IF	Citations
73	El papel emergente de la radiómica en la EPOC y el cáncer de pulmón. Karger Kompass NeumologÃa, 2020, , 46-53.	0.0	О
74	Non-invasive imaging prediction of tumor hypoxia: A novel developed and externally validated CT and FDG-PET-based radiomic signatures. Radiotherapy and Oncology, 2020, 153, 97-105.	0.3	19
75	Radiomics based on baseline DCE-MRI is predictive of tumor pathological complete response to neoadjuvant systemic therapy in breast cancer patients. European Journal of Surgical Oncology, 2020, 46, e23.	0.5	O
76	[18F]-HX4 PET/CT hypoxia in patients with squamous cell carcinoma of the head and neck treated with chemoradiotherapy: Prognostic results from two prospective trials. Clinical and Translational Radiation Oncology, 2020, 23, 9-15.	0.9	12
77	Hypoxia-Activated Prodrug Derivatives of Carbonic Anhydrase Inhibitors in Benzenesulfonamide Series: Synthesis and Biological Evaluation. Molecules, 2020, 25, 2347.	1.7	8
78	Human fibronectin extra domain B as a biomarker for targeted therapy in cancer. Molecular Oncology, 2020, 14, 1555-1568.	2.1	29
79	Lymphocyte-Sparing Radiotherapy: The Rationale for Protecting Lymphocyte-rich Organs When Combining Radiotherapy With Immunotherapy. Seminars in Radiation Oncology, 2020, 30, 187-193.	1.0	57
80	Hypoxia PET Imaging with [18F]-HX4—A Promising Next-Generation Tracer. Cancers, 2020, 12, 1322.	1.7	35
81	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. BMC Cancer, 2020, 20, 557.	1.1	29
82	Mitochondrial Dysfunction Inhibits Hypoxia-Induced HIF- $1\hat{l}\pm$ Stabilization and Expression of Its Downstream Targets. Frontiers in Oncology, 2020, 10, 770.	1.3	16
83	Privacy-preserving distributed learning of radiomics to predict overall survival and HPV status in head and neck cancer. Scientific Reports, 2020, 10, 4542.	1.6	46
84	Fitter Mitochondria Are Associated With Radioresistance in Human Head and Neck SQD9 Cancer Cells. Frontiers in Pharmacology, 2020, 11, 263.	1.6	19
85	Systematic Review of Privacy-Preserving Distributed Machine Learning From Federated Databases in Health Care. JCO Clinical Cancer Informatics, 2020, 4, 184-200.	1.0	72
86	The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. Radiology, 2020, 295, 328-338.	3.6	1,869
87	Development of a Clinical Decision Support System for Severity Risk Prediction and Triage of COVID-19 Patients at Hospital Admission: an International Multicenter Study. European Respiratory Journal, 2020, 56, 2001104.	3.1	172
88	Radiomics: from qualitative to quantitative imaging. British Journal of Radiology, 2020, 93, 20190948.	1.0	164
89	Deep learning in fracture detection: a narrative review. Monthly Notices of the Royal Astronomical Society: Letters, 2020, 91, 215-220.	1.2	81
90	The Emerging Role of Radiomics in COPD and Lung Cancer. Respiration, 2020, 99, 99-107.	1.2	33

#	Article	IF	Citations
91	Preoperative CT-based radiomics combined with intraoperative frozen section is predictive of invasive adenocarcinoma in pulmonary nodules: a multicenter study. European Radiology, 2020, 30, 2680-2691.	2.3	24
92	Late Breaking Abstract - Development and validation of an automated radiomic CT signature for detecting? COVID-19. , 2020, , .		1
93	Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy. PLoS ONE, 2020, 15, e0232639.	1.1	35
94	EXTH-30. EXPANDING THE UTILITY OF PRE-CLINICAL CONTRAST ENHANCED CT (CE-CT) FOR TUMOR DETECTION IN ORTHOTOPIC GBM MODELS USING RADIOMICS. Neuro-Oncology, 2020, 22, ii93-ii93.	0.6	0
95	Title is missing!. , 2020, 15, e0232639.		0
96	Title is missing!. , 2020, 15, e0232639.		0
97	Title is missing!. , 2020, 15, e0232639.		0
98	Title is missing!. , 2020, 15, e0232639.		0
99	Computed Tomography-based Radiomics for Risk Stratification in Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 448-456.	0.4	41
100	Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity. Radiotherapy and Oncology, 2019, 141, 247-255.	0.3	19
101	Development and validation of a patient decision aid for prostate Cancer therapy: from paternalistic towards participative shared decision making. BMC Medical Informatics and Decision Making, 2019, 19, 130.	1.5	26
102	SP-0687 Combining Radiotherapy with Immunotherapy: focus on immunocytokines. Radiotherapy and Oncology, 2019, 133, S358-S359.	0.3	0
103	OC-0407 CT-based Radiomics for Risk Stratification in Prostate Cancer. Radiotherapy and Oncology, 2019, 133, S209.	0.3	0
104	PO-0855 Development and Validation of a Prostate Cancer Patient Decision Aid: Towards Participative Medicine. Radiotherapy and Oncology, 2019, 133, S450-S451.	0.3	0
105	Improving decision making in larynx cancer by developing a decision aid: A mixed methods approach. Laryngoscope, 2019, 129, 2733-2739.	1.1	21
106	Ano-rectal wall dose-surface maps localize the dosimetric benefit of hydrogel rectum spacers in prostate cancer radiotherapy. Clinical and Translational Radiation Oncology, 2019, 14, 17-24.	0.9	11
107	Radiomics Analysis for Clinical Decision Support in Nuclear Medicine. Seminars in Nuclear Medicine, 2019, 49, 438-449.	2.5	38
108	Challenges and caveats of a multi-center retrospective radiomics study: an example of early treatment response assessment for NSCLC patients using FDG-PET/CT radiomics. PLoS ONE, 2019, 14, e0217536.	1.1	38

#	Article	IF	Citations
109	Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. European Journal of Cancer, 2019, 114, 128-136.	1.3	8
110	Longitudinal radiomics of cone-beam CT images from non-small cell lung cancer patients: Evaluation of the added prognostic value for overall survival and locoregional recurrence. Radiotherapy and Oncology, 2019, 136, 78-85.	0.3	48
111	Stability of radiomics features in apparent diffusion coefficient maps from a multi-centre test-retest trial. Scientific Reports, 2019, 9, 4800.	1.6	93
112	Decision Support Systems in Oncology. JCO Clinical Cancer Informatics, 2019, 3, 1-9.	1.0	85
113	Impact of <scp>SBRT</scp> fractionation in hypoxia dose painting — Accounting for heterogeneous and dynamic tumor oxygenation. Medical Physics, 2019, 46, 2512-2521.	1.6	17
114	Characterizing geometrical accuracy in clinically optimised 7T and 3T magnetic resonance images for high-precision radiation treatment of brain tumours. Physics and Imaging in Radiation Oncology, 2019, 9, 35-42.	1.2	17
115	Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials. Clinical and Translational Radiation Oncology, 2019, 15, 62-69.	0.9	86
116	NIMG-65. PREDICTING PROGNOSIS AND CANCER HOTSPOT MUTATIONS USING QUALITATIVE MR IMAGING ANALYSIS IN GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi176-vi176.	0.6	0
117	Performing clinical 18F-FDG-PET/MRI of the mediastinum optimising a dedicated, patient-friendly protocol. Nuclear Medicine Communications, 2019, 40, 815-826.	0.5	3
118	Genetic Variants Predict Optimal Timing of Radiotherapy to Reduce Side-effects in Breast Cancer Patients. Clinical Oncology, 2019, 31, 9-16.	0.6	30
119	Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric <i>in silico</i> ROCOCO trial. Acta Oncológica, 2019, 58, 57-65.	0.8	20
120	Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patients—An external validation. European Journal of Radiology, 2019, 110, 148-155.	1.2	22
121	Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation. Frontiers in Oncology, 2019, 9, 1470.	1.3	19
122	Role of hypoxia-activated prodrugs in combination with radiation therapy: An <i>in silico</i> approach. Mathematical Biosciences and Engineering, 2019, 16, 6257-6273.	1.0	11
123	The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses. Oncolmmunology, 2018, 7, e1414119.	2.1	36
124	How Advances in Imaging Will Affect Precision Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2018, 101, 292-298.	0.4	37
125	A biodegradable rectal balloon implant to protect the rectum during prostate cancer radiotherapy for a patient with active Crohnâ $\in$ <sup>M</sup> s disease. Technical Innovations and Patient Support in Radiation Oncology, 2018, 6, 1-4.	0.6	5
126	Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study. British Journal of Radiology, 2018, 91, 20170498.	1.0	109

#	Article	IF	CITATIONS
127	Evidence on the efficacy of primary radiosurgery or stereotactic radiotherapy for drug-resistant non-neoplastic focal epilepsy in adults: A systematic review. Seizure: the Journal of the British Epilepsy Association, 2018, 55, 83-92.	0.9	10
128	Improved effectiveness of stereotactic radiosurgery in large brain metastases by individualized isotoxic dose prescription: an in silico study. Strahlentherapie Und Onkologie, 2018, 194, 560-569.	1.0	26
129	Targeting Hypoxia to Improve Non–Small Cell Lung Cancer Outcome. Journal of the National Cancer Institute, 2018, 110, 14-30.	3.0	177
130	A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy. Acta $Oncol\tilde{A}^3$ gica, 2018, 57, 226-230.	0.8	35
131	Multi-Scale Modeling and Oxygen Impact on Tumor Temporal Evolution: Application on Rectal Cancer During Radiotherapy. IEEE Transactions on Medical Imaging, 2018, 37, 871-880.	5.4	5
132	The posterior cerebellum, a new organ at risk?. Clinical and Translational Radiation Oncology, 2018, 8, 22-26.	0.9	23
133	Non-linear conversion of HX4 uptake for automatic segmentation of hypoxic volumes and dose prescription. Acta Oncol $ ilde{A}^3$ gica, 2018, 57, 485-490.	0.8	8
134	Fractal-based radiomic approach to predict complete pathological response after chemo-radiotherapy in rectal cancer. Radiologia Medica, 2018, 123, 286-295.	4.7	91
135	[I232] Radiomics: Transforming standard imaging into mineable data related to biology. Physica Medica, 2018, 52, 87.	0.4	0
136	Novel fluorinated carbonic anhydrase IX inhibitors reduce hypoxia-induced acidification and clonogenic survival of cancer cells. Oncotarget, 2018, 9, 26800-26816.	0.8	25
137	Pathway-based subnetworks enable cross-disease biomarker discovery. Nature Communications, 2018, 9, 4746.	5.8	30
138	Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients. PLoS ONE, 2018, 13, e0207362.	1.1	31
139	A Deep Look Into the Future of Quantitative Imaging in Oncology: A Statement of Working Principles and Proposal for Change. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1074-1082.	0.4	86
140	The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1219-1235.	0.4	30
141	Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget, 2018, 9, 16932-16950.	0.8	109
142	Tracking tumor biology with radiomics: A systematic review utilizing a radiomics quality score. Radiotherapy and Oncology, 2018, 127, 349-360.	0.3	175
143	Machine learning algorithms for outcome prediction in (chemo)radiotherapy: An empirical comparison of classifiers. Medical Physics, 2018, 45, 3449-3459.	1.6	214
144	Development of an isotoxic decision support system integrating genetic markers of toxicity for the implantation of a rectum spacer. Acta Oncol $\tilde{A}^3$ gica, 2018, 57, 1499-1505.	0.8	6

#	Article	IF	Citations
145	Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer. Acta OncolA³gica, 2018, 57, 1475-1481.	0.8	58
146	Towards a Clinical Decision Support System for External Beam Radiation Oncology Prostate Cancer Patients: Proton vs. Photon Radiotherapy? A Radiobiological Study of Robustness and Stability. Cancers, 2018, 10, 55.	1.7	5
147	Stereotactic Radiosurgery in the Management of Patients With Brain Metastases of Non-Small Cell Lung Cancer: Indications, Decision Tools and Future Directions. Frontiers in Oncology, 2018, 8, 154.	1.3	40
148	Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer. Lung Cancer, 2018, 124, 6-11.	0.9	39
149	18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) – A prospective externally validated study. PLoS ONE, 2018, 13, e0192859.	1.1	57
150	Magnetic Resonance, Vendor-independent, Intensity Histogram Analysis Predicting Pathologic Complete Response After Radiochemotherapy of Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 765-774.	0.4	81
151	Nitroimidazole-based inhibitors DTP338 and DTP348 are safe for zebrafish embryos and efficiently inhibit the activity of human CA IX in <i>Xenopus</i> Oocytes. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1064-1073.	2.5	14
152	Decision support systems for personalized and participative radiation oncology. Advanced Drug Delivery Reviews, 2017, 109, 131-153.	6.6	113
153	Defining the hypoxic target volume based on positron emission tomography for image guided radiotherapy ${\bf \hat{a}} \in {\bf \hat{e}}$ the influence of the choice of the reference region and conversion function. Acta Oncol ${\bf \hat{A}}^3$ gica, 2017, 56, 819-825.	0.8	13
154	Individualized early death and long-term survival prediction after stereotactic radiosurgery for brain metastases of non-small cell lung cancer: Two externally validated nomograms. Radiotherapy and Oncology, 2017, 123, 189-194.	0.3	29
155	Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. Radiotherapy and Oncology, 2017, 123, 363-369.	0.3	136
156	Developing and Validating a Survival Prediction Model for NSCLC Patients Through Distributed Learning Across 3 Countries. International Journal of Radiation Oncology Biology Physics, 2017, 99, 344-352.	0.4	102
157	Combining radiotherapy with immunotherapy: the past, the present and the future. British Journal of Radiology, 2017, 90, 20170157.	1.0	99
158	A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the "Low Drug Uptake Volume― Radiotherapy and Oncology, 2017, 124, 513-520.	0.3	22
159	Big Data in radiation therapy: challenges and opportunities. British Journal of Radiology, 2017, 90, 20160689.	1.0	22
160	PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer. Radiotherapy and Oncology, 2017, 122, 267-273.	0.3	48
161	Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. British Journal of Radiology, 2017, 90, 20160665.	1.0	270
162	Radiomics: the bridge between medical imaging and personalized medicine. Nature Reviews Clinical Oncology, 2017, 14, 749-762.	12.5	3,216

#	Article	IF	Citations
163	Development of a virtual spacer to support the decision for the placement of an implantable rectum spacer for prostate cancer radiotherapy: Comparison of dose, toxicity and cost-effectiveness. Radiotherapy and Oncology, 2017, 125, 107-112.	0.3	23
164	Feature selection methodology for longitudinal cone-beam CT radiomics. Acta Oncol $\tilde{A}^3$ gica, 2017, 56, 1537-1543.	0.8	55
165	Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT. Acta Oncol $\tilde{A}^3$ gica, 2017, 56, 1591-1596.	0.8	15
166	A framework based on hidden Markov trees for multimodal <scp>PET</scp> / <scp>CT</scp> image coâ€segmentation. Medical Physics, 2017, 44, 5835-5848.	1.6	9
167	Quality assessment of positron emission tomography scans: recommendations for future multicentre trials. Acta Oncol $\tilde{A}^3$ gica, 2017, 56, 1459-1464.	0.8	11
168	Influence of gray level discretization on radiomic feature stability for different CT scanners, tube currents and slice thicknesses: a comprehensive phantom study. Acta Oncológica, 2017, 56, 1544-1553.	0.8	183
169	Infrastructure and distributed learning methodology for privacy-preserving multi-centric rapid learning health care: euroCAT. Clinical and Translational Radiation Oncology, 2017, 4, 24-31.	0.9	98
170	Hypoxia and hypoxia response-associated molecular markers in esophageal cancer: A systematic review. Methods, 2017, 130, 51-62.	1.9	42
171	What is the impact of innovation on output in healthcare with a special focus on treatment innovations in radiotherapy? A literature review. British Journal of Radiology, 2017, 90, 20170251.	1.0	13
172	4DCT imaging to assess radiomics feature stability: An investigation for thoracic cancers. Radiotherapy and Oncology, 2017, 125, 147-153.	0.3	61
173	Post-radiochemotherapy PET radiomics in head and neck cancer – The influence of radiomics implementation on the reproducibility of local control tumor models. Radiotherapy and Oncology, 2017, 125, 385-391.	0.3	89
174	MODEL-BASED COST-EFFECTIVENESS OF CONVENTIONAL AND INNOVATIVE CHEMO-RADIATION IN LUNG CANCER. International Journal of Technology Assessment in Health Care, 2017, 33, 681-690.	0.2	3
175	Clustering of multi-parametric functional imaging to identify high-risk subvolumes in non-small cell lung cancer. Radiotherapy and Oncology, 2017, 125, 379-384.	0.3	23
176	Prospective validation of pathologic complete response models in rectal cancer: Transferability and reproducibility. Medical Physics, 2017, 44, 4961-4967.	1.6	8
177	Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status. Oral Oncology, 2017, 71, 150-155.	0.8	92
178	[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 8-16.	3.3	20
179	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	12.5	792
180	New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs. European Journal of Medicinal Chemistry, 2017, 127, 691-702.	2.6	22

#	Article	IF	Citations
181	Radial gradient and radial deviation radiomic features from pre-surgical CT scans are associated with survival among lung adenocarcinoma patients. Oncotarget, 2017, 8, 96013-96026.	0.8	26
182	Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. Frontiers in Oncology, 2017, 7, 83.	1.3	36
183	Defining the biological basis of radiomic phenotypes in lung cancer. ELife, 2017, 6, .	2.8	258
184	Distinct radiation responses after in vitro mtDNA depletion are potentially related to oxidative stress. PLoS ONE, 2017, 12, e0182508.	1.1	23
185	Whole brain radiotherapy versus stereotactic radiosurgery for 4–10 brain metastases: a phase III randomised multicentre trial. BMC Cancer, 2017, 17, 500.	1.1	41
186	Implantation of a biodegradable rectum balloon implant: Tips, Tricks and Pitfalls. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 1033-1042.	0.7	15
187	Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach. Oncotarget, 2017, 8, 3870-3880.	0.8	48
188	Test–Retest Data for Radiomics Feature Stability Analysis: Generalizable or Study-Specific?. Tomography, 2016, 2, 361-365.	0.8	135
189	Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?. BioMed Research International, 2016, 2016, 1-14.	0.9	44
190	Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis. Frontiers in Oncology, 2016, 6, 69.	1.3	129
191	Exploratory Study to Identify Radiomics Classifiers for Lung Cancer Histology. Frontiers in Oncology, 2016, 6, 71.	1.3	306
192	Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress. Cancers, 2016, 8, 63.	1.7	28
193	What is the degree of innovation routinely implemented in Dutch radiotherapy centres? A multicentre cross-sectional study. British Journal of Radiology, 2016, 89, 20160601.	1.0	7
194	Distributed learning: Developing a predictive model based on data from multiple hospitals without data leaving the hospital – A real life proof of concept. Radiotherapy and Oncology, 2016, 121, 459-467.	0.3	139
195	Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement. Radiotherapy and Oncology, 2016, 121, 440-446.	0.3	15
196	A validated tumor control probability model based on a metaâ€analysis of low, intermediate, and highâ€risk prostate cancer patients treated by photon, proton, or carbonâ€ion radiotherapy. Medical Physics, 2016, 43, 734-747.	1.6	17
197	Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer – A survival model with external validation. Radiotherapy and Oncology, 2016, 119, 487-494.	0.3	32
198	Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells. Molecular Pharmaceutics, 2016, 13, 2010-2025.	2.3	37

#	Article	IF	Citations
199	Who will benefit most from hydrogel rectum spacer implantation in prostate cancer radiotherapy? A model-based approach for patient selection. Radiotherapy and Oncology, 2016, 121, 118-123.	0.3	31
200	Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study. Radiotherapy and Oncology, 2016, 121, 322-327.	0.3	12
201	Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicentric in silico ROCOCO trial. Radiotherapy and Oncology, 2016, 121, 387-394.	0.3	46
202	How efficient is translational research in radiation oncology? The example of a large Dutch academic radiation oncology department. British Journal of Radiology, 2016, 89, 20160129.	1.0	8
203	A phase 1 â€~window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. BMC Cancer, 2016, 16, 644.	1.1	22
204	Synthesis and in Vivo Biological Evaluation of <sup>68</sup> Ga-Labeled Carbonic Anhydrase IX Targeting Small Molecules for Positron Emission Tomography. Journal of Medicinal Chemistry, 2016, 59, 6431-6443.	2.9	33
205	Development and evaluation of an online three-level proton vs photon decision support prototype for head and neck cancer – Comparison of dose, toxicity and cost-effectiveness. Radiotherapy and Oncology, 2016, 118, 281-285.	0.3	65
206	Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2139-2146.	3.3	51
207	Technical feasibility of integrating 7ÂT anatomical MRI in image-guided radiotherapy of glioblastoma: a preparatory study. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2016, 29, 591-603.	1.1	14
208	Increasing the Therapeutic Ratio of Stereotactic Ablative Radiotherapy by Individualized Isotoxic Dose Prescription. Journal of the National Cancer Institute, 2016, 108, djv305.	3.0	34
209	Multistate Statistical Modeling. Medical Decision Making, 2016, 36, 86-100.	1.2	8
210	Standardized data collection to build prediction models in oncology: a prototype for rectal cancer. Future Oncology, 2016, 12, 119-136.	1.1	32
211	The Quest for Evidence for Proton Therapy: Model-Based Approach and Precision Medicine. International Journal of Radiation Oncology Biology Physics, 2016, 95, 30-36.	0.4	105
212	Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 240-248.	3.3	64
213	Quantification of CT-assessed radiation-induced lung damage in lung cancer patients treated with or without chemotherapy and cetuximab. Acta Oncol $ ilde{A}^3$ gica, 2016, 55, 156-162.	0.8	11
214	In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity. Scientific Reports, 2016, 6, 22198.	1.6	8
215	Fractionated Radiotherapy with 3 $\times$ 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response. PLoS ONE, 2016, 11, e0159515.	1.1	40
216	The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy. PLoS ONE, 2016, 11, e0161040.	1.1	14

#	Article	lF	CITATIONS
217	Machine Learning methods for Quantitative Radiomic Biomarkers. Scientific Reports, 2015, 5, 13087.	1.6	744
218	The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis. Scientific Reports, 2015, 5, 11075.	1.6	318
219	PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes. Radiotherapy and Oncology, 2015, 116, 281-286.	0.3	64
220	How to measure innovation in radiotherapy: an application of the Delphi method. Journal of Hospital Administration, 2015, 4, 14.	0.0	2
221	Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro in v	0.8	76
222	Radiomic Machine-Learning Classifiers for Prognostic Biomarkers of Head and Neck Cancer. Frontiers in Oncology, 2015, 5, 272.	1.3	318
223	A Comparative Study of the Hypoxia PET Tracers [18F]HX4, [18F]FAZA, and [18F]FMISO in a Preclinical Tumor Model. International Journal of Radiation Oncology Biology Physics, 2015, 91, 351-359.	0.4	139
224	Radiomic feature clusters and Prognostic Signatures specific for Lung and Head & Deck cancer. Scientific Reports, 2015, 5, 11044.	1.6	384
225	Quantitative Computed Tomographic Descriptors Associate Tumor Shape Complexity and Intratumor Heterogeneity with Prognosis in Lung Adenocarcinoma. PLoS ONE, 2015, 10, e0118261.	1.1	207
226	Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung. Clinical Cancer Research, 2015, 21, 1477-1486.	3.2	13
227	Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2. Oncolmmunology, 2015, 4, e1021541.	2.1	18
228	Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model. Radiotherapy and Oncology, 2015, 116, 438-442.	0.3	30
229	A phase l–II study on the combination of rapamycin and short course radiotherapy in rectal cancer. Radiotherapy and Oncology, 2015, 116, 214-220.	0.3	17
230	The influence of gastric filling instructions on dose delivery in patients with oesophageal cancer: A prospective study. Radiotherapy and Oncology, 2015, 117, 442-447.	0.3	10
231	The transcriptomic profile of ovarian cancer grading. Cancer Medicine, 2015, 4, 56-64.	1.3	2
232	Evaluating Tumor Response of Non-Small Cell Lung Cancer Patients With 18F-Fludeoxyglucose Positron Emission Tomography: Potential for Treatment Individualization. International Journal of Radiation Oncology Biology Physics, 2015, 91, 376-384.	0.4	27
233	[18F]VM4-037 MicroPET Imaging and Biodistribution of Two In Vivo CAIX-Expressing Tumor Models. Molecular Imaging and Biology, 2015, 17, 615-619.	1.3	40
234	Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma. Acta Oncol $\tilde{A}^3$ gica, 2015, 54, 1378-1384.	0.8	17

#	Article	IF	Citations
235	TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging. Clinical Cancer Research, 2015, 21, 2984-2992.	3.2	95
236	ls there a causal relationship between genetic changes and radiomics-based image features? An in vivo preclinical experiment with doxycycline inducible GADD34 tumor cells. Radiotherapy and Oncology, 2015, 116, 462-466.	0.3	106
237	Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects. Clinical Cancer Research, 2015, 21, 1151-1160.	3.2	79
238	Probabilistic evaluation of target dose deterioration in dose painting by numbers for stage II/III lung cancer. Practical Radiation Oncology, 2015, 5, e375-e382.	1.1	7
239	Individualized Positron Emission Tomography–Based Isotoxic Accelerated Radiation Therapy Is Cost-Effective Compared With Conventional Radiation Therapy: A Model-Based Evaluation. International Journal of Radiation Oncology Biology Physics, 2015, 91, 857-865.	0.4	6
240	Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer. Radiotherapy and Oncology, 2015, 114, 302-309.	0.3	49
241	CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiotherapy and Oncology, 2015, 114, 345-350.	0.3	576
242	A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients. International Journal of Radiation Oncology Biology Physics, 2015, 92, 935-944.	0.4	83
243	Spacers in radiotherapy treatment of prostate cancer: Is reduction of toxicity cost-effective?. Radiotherapy and Oncology, 2015, 114, 276-281.	0.3	49
244	What Level of Accuracy Is Achievable for Preclinical Dose Painting Studies on a Clinical Irradiation Platform?. Radiation Research, 2015, 183, 501.	0.7	7
245	Modern clinical research: How rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine. Acta Oncológica, 2015, 54, 1289-1300.	0.8	59
246	Repeatability of hypoxia PET imaging using [18F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1840-1849.	3.3	55
247	High dose rate and flattening filter free irradiation can be safely implemented in clinical practice. International Journal of Radiation Biology, 2015, 91, 778-785.	1.0	12
248	Chronic radiation proctitis: tricks to prevent and treat. International Journal of Colorectal Disease, 2015, 30, 1293-1303.	1.0	87
249	Preclinical Assessment of Efficacy of Radiation Dose Painting Based on Intratumoral FDG-PET Uptake. Clinical Cancer Research, 2015, 21, 5511-5518.	3.2	23
250	External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma. Acta OncolA³gica, 2015, 54, 1423-1429.	0.8	195
251	New ways to image and target tumour hypoxia and its molecular responses. Radiotherapy and Oncology, 2015, 116, 352-357.	0.3	49
252	Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 689-721.	2.5	93

#	Article	IF	Citations
253	Clostridium to treat cancer: dream or reality?. Annals of Translational Medicine, 2015, 3, S21.	0.7	13
254	Rapid Point-Of-Care Breath Test for Biomarkers of Breast Cancer and Abnormal Mammograms. PLoS ONE, 2014, 9, e90226.	1.1	48
255	Robust Radiomics Feature Quantification Using Semiautomatic Volumetric Segmentation. PLoS ONE, 2014, 9, e102107.	1.1	488
256	Reversal of Hypoxia in Murine Atherosclerosis Prevents Necrotic Core Expansion by Enhancing Efferocytosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2545-2553.	1.1	56
257	Nomogram predicting response after chemoradiotherapy in rectal cancer using sequential PETCT imaging: A multicentric prospective study with external validation. Radiotherapy and Oncology, 2014, 113, 215-222.	0.3	51
258	Creating a data exchange strategy for radiotherapy research: Towards federated databases and anonymised public datasets. Radiotherapy and Oncology, 2014, 113, 303-309.	0.3	79
259	A qualitative synthesis of the evidence behind elective lymph node irradiation in oesophageal cancer. Radiotherapy and Oncology, 2014, 113, 166-174.	0.3	22
260	A Phase I Study of Concurrent Individualized, Isotoxic Accelerated Radiotherapy and Cisplatin–Vinorelbine–Cetuximab in Patients With Stage III Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 710-716.	0.5	20
261	Externally validated HPV-based prognostic nomogram for oropharyngeal carcinoma patients yields more accurate predictions than TNM staging. Radiotherapy and Oncology, 2014, 113, 324-330.	0.3	72
262	Rapid learning in practice: A lung cancer survival decision support system in routine patient care data. Radiotherapy and Oncology, 2014, 113, 47-53.	0.3	41
263	Particle Therapy for Non-Small Cell Lung Tumors: Where Do We Stand? A Systematic Review of the Literature. Frontiers in Oncology, 2014, 4, 292.	1.3	54
264	<i>In Vivo</i> Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging. Clinical Cancer Research, 2014, 20, 6389-6397.	3.2	81
265	Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR). Radiotherapy and Oncology, 2014, 110, 482-487.	0.3	30
266	Development and biological evaluation of 99mTc-sulfonamide derivatives for inÂvivo visualization of CAIX as surrogate tumor hypoxia markers. European Journal of Medicinal Chemistry, 2014, 71, 374-384.	2.6	41
267	Blood biomarkers are helpful in the prediction of response to chemoradiation in rectal cancer: A prospective, hypothesis driven study on patients with locally advanced rectal cancer. Radiotherapy and Oncology, 2014, 111, 237-242.	0.3	42
268	Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nature Communications, 2014, 5, 4006.	5.8	3,355
269	A let-7 microRNA polymorphism in the KRAS 3′-UTR is prognostic in oropharyngeal cancer. Cancer Epidemiology, 2014, 38, 591-598.	0.8	19
270	Ensemble analyses improve signatures of tumour hypoxia and reveal inter-platform differences. BMC Bioinformatics, 2014, 15, 170.	1.2	35

#	Article	IF	Citations
271	Systematic analysis of 18F-FDG PET and metabolism, proliferation and hypoxia markers for classification of head and neck tumors. BMC Cancer, 2014, 14, 130.	1.1	19
272	International data-sharing for radiotherapy research: An open-source based infrastructure for multicentric clinical data mining. Radiotherapy and Oncology, 2014, 110, 370-374.	0.3	67
273	Edmond-Philippe Malaise (1930-2013): A Lifetime of Perseverance Leads to the Cellular Definition of Intrinsic Radiosensitivity. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1215-1217.	0.4	1
274	What to choose as radical local treatment for lung metastases from colo-rectal cancer: Surgery or radiofrequency ablation?. Cancer Treatment Reviews, 2014, 40, 60-67.	3.4	52
275	A prospective study comparing the predictions of doctors versus models for treatment outcome of lung cancer patients: A step toward individualized care and shared decision making. Radiotherapy and Oncology, 2014, 112, 37-43.	0.3	77
276	Epigenetics in radiotherapy: Where are we heading?. Radiotherapy and Oncology, 2014, 111, 168-177.	0.3	43
277	Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: A new concept of dual targeting drugs. Radiotherapy and Oncology, 2013, 108, 523-528.	0.3	80
278	Selection of patients for radiotherapy with protons aiming at reduction of side effects: The model-based approach. Radiotherapy and Oncology, 2013, 107, 267-273.	0.3	408
279	Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer. Radiotherapy and Oncology, 2013, 109, 65-70.	0.3	37
280	Benefits of a clinical data warehouse with data mining tools to collect data for a radiotherapy trial. Radiotherapy and Oncology, 2013, 108, 174-179.	0.3	62
281	â€~Rapid Learning health care in oncology' – An approach towards decision support systems enabling customised radiotherapy'. Radiotherapy and Oncology, 2013, 109, 159-164.	0.3	175
282	Interview: Lung cancer: a very challenging disease. Lung Cancer Management, 2013, 2, 461-465.	1.5	0
283	Automated delineation of lung tumors from CT images using a single click ensemble segmentation approach. Pattern Recognition, 2013, 46, 692-702.	5.1	138
284	Predicting outcomes in radiation oncology—multifactorial decision support systems. Nature Reviews Clinical Oncology, 2013, 10, 27-40.	12.5	329
285	Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients. Radiotherapy and Oncology, 2013, 109, 100-106.	0.3	50
286	Hypoxia imaging with [18F]HX4 PET in NSCLC patients: Defining optimal imaging parameters. Radiotherapy and Oncology, 2013, 109, 58-64.	0.3	81
287	Protons in Head-and-Neck Cancer: Bridging the Gap of Evidence. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1282-1288.	0.4	71
288	High NOTCH activity induces radiation resistance in non small cell lung cancer. Radiotherapy and Oncology, 2013, 108, 440-445.	0.3	60

#	Article	IF	CITATIONS
289	An in silico comparison between margin-based and probabilistic target-planning approaches in head and neck cancer patients. Radiotherapy and Oncology, 2013, 109, 430-436.	0.3	14
290	State of the Art Radiation Therapy for Lung Cancer 2012: A Glimpse of the Future. Clinical Lung Cancer, 2013, 14, 89-95.	1,1	38
291	Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer. Radiotherapy and Oncology, 2013, 107, 184-188.	0.3	42
292	Total Gross Tumor Volume Is an Independent Prognostic Factor in Patients Treated With Selective Nodal Irradiation for Stage I to III Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1319-1324.	0.4	39
293	Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. BMC Cancer, 2013, 13, 84.	1.1	113
294	Hypoxia-Targeting Carbonic Anhydrase IX Inhibitors by a New Series of Nitroimidazole-Sulfonamides/Sulfamides/Sulfamates. Journal of Medicinal Chemistry, 2013, 56, 8512-8520.	2.9	76
295	Early prediction of pathological response in locally advanced rectal cancer based on sequential $\frac{3}{6}$ can sequential $\frac{3}{6}$ cancer based on $\frac{3}{6}$ cancer b	0.8	40
296	Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer. Acta Oncol $\tilde{A}^3$ gica, 2013, 52, 1398-1404.	0.8	44
297	Stability of FDG-PET Radiomics features: An integrated analysis of test-retest and inter-observer variability. Acta Oncológica, 2013, 52, 1391-1397.	0.8	353
298	PERK/eIF2α signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROS. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4622-4627.	3.3	193
299	Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage <scp>III</scp> non–small cell lung cancer. Cancer Medicine, 2013, 2, 916-924.	1.3	29
300	Magnetic Resonance Guided High-Intensity Focused Ultrasound Mediated Hyperthermia Improves the Intratumoral Distribution of Temperature-Sensitive Liposomal Doxorubicin. Investigative Radiology, 2013, 48, 395-405.	3.5	60
301	Volumetric CT-based segmentation of NSCLC using 3D-Slicer. Scientific Reports, 2013, 3, 3529.	1.6	168
302	The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e67876.	1.1	31
303	Results of a Multicentric In Silico Clinical Trial (ROCOCO): Comparing Radiotherapy with Photons and Protons for Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 165-176.	0.5	89
304	Radical Treatment of Non–Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct01282450). Journal of Thoracic Oncology, 2012, 7, 1547-1555.	0.5	251
305	Radiomics: the process and the challenges. Magnetic Resonance Imaging, 2012, 30, 1234-1248.	1.0	1,675
306	Should Patient Setup in Lung Cancer Be Based on the Primary Tumor? An Analysis of Tumor Coverage and Normal Tissue Dose Using Repeated Positron Emission Tomography/Computed Tomography Imaging. International Journal of Radiation Oncology Biology Physics, 2012, 82, 379-385.	0.4	8

#	Article	IF	CITATIONS
307	Repeated Positron Emission Tomography-Computed Tomography and Perfusion-Computed Tomography Imaging in Rectal Cancer: Fluorodeoxyglucose Uptake Corresponds With Tumor Perfusion. International Journal of Radiation Oncology Biology Physics, 2012, 82, 849-855.	0.4	11
308	PET-Based Treatment Response Evaluation in Rectal Cancer: Prediction and Validation. International Journal of Radiation Oncology Biology Physics, 2012, 82, 871-876.	0.4	44
309	Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: A prospective population-based study. Radiotherapy and Oncology, 2012, 102, 228-233.	0.3	40
310	Is it time for tailored treatment of rectal cancer? From prescribing by consensus to prescribing by numbers. Radiotherapy and Oncology, 2012, 102, 1-3.	0.3	20
311	FDG–PET–CT reduces the interobserver variability in rectal tumor delineation. Radiotherapy and Oncology, 2012, 102, 371-376.	0.3	53
312	The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer. Radiotherapy and Oncology, 2012, 102, 436-443.	0.3	50
313	No association between TGF- $\hat{l}^21$ polymorphisms and radiation-induced lung toxicity in a European cohort of lung cancer patients. Radiotherapy and Oncology, 2012, 105, 296-298.	0.3	30
314	Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiotherapy and Oncology, 2012, 105, 145-149.	0.3	89
315	Radiomics: Extracting more information from medical images using advanced feature analysis. European Journal of Cancer, 2012, 48, 441-446.	1.3	3,846
316	Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer. European Journal of Cancer, 2012, 48, 2339-2346.	1.3	65
317	Response Assessment Using <sup>18</sup> F-FDG PET Early in the Course of Radiotherapy Correlates with Survival in Advanced-Stage Non–Small Cell Lung Cancer. Journal of Nuclear Medicine, 2012, 53, 1514-1520.	2.8	106
318	Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: A prospective validation. Lung Cancer, 2012, 75, 73-76.	0.9	97
319	Functional MRI for radiotherapy dose painting. Magnetic Resonance Imaging, 2012, 30, 1216-1223.	1.0	136
320	A semiautomatic CT-based ensemble segmentation of lung tumors: Comparison with oncologists' delineations and with the surgical specimen. Radiotherapy and Oncology, 2012, 105, 167-173.	0.3	99
321	Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. Genome Medicine, 2012, 4, 84.	3.6	15
322	How Should Data Be Shared and Rapid Learning Health Care Promoted?., 2012,, 355-364.		0
323	Systematic review and meta-analysis of radiotherapy in various head and neck cancers: Comparing photons, carbon-ions and protons. Cancer Treatment Reviews, 2011, 37, 185-201.	3.4	86
324	Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer. Cancer Treatment Reviews, 2011, 37, 331-343.	3.4	38

#	Article	IF	CITATIONS
325	Treatment with curative intent of stage III non-small cell lung cancer patients of 75years: A prospective population-based study. European Journal of Cancer, 2011, 47, 2691-2697.	1.3	34
326	FDG-PET provides the best correlation with the tumor specimen compared to MRI and CT in rectal cancer. Radiotherapy and Oncology, 2011, 98, 270-276.	0.3	51
327	Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging. Radiotherapy and Oncology, 2011, 98, 126-133.	0.3	89
328	Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage lâ€"III small cell lung cancer: A hypothesis generating study. Radiotherapy and Oncology, 2011, 99, 172-175.	0.3	42
329	Residual metabolic tumor activity after chemo-radiotherapy is mainly located in initially high FDG uptake areas in rectal cancer. Radiotherapy and Oncology, 2011, 99, 137-141.	0.3	30
330	E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiotherapy and Oncology, 2011, 99, 392-397.	0.3	210
331	Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiotherapy and Oncology, 2011, 99, 424-431.	0.3	156
332	Translational control is a major contributor to hypoxia induced gene expression. Radiotherapy and Oncology, 2011, 99, 379-384.	0.3	37
333	miR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer. Radiotherapy and Oncology, 2011, 101, 203-208.	0.3	37
334	Development and validation of a nomogram for prediction of survival and local control in laryngeal carcinoma patients treated with radiotherapy alone: A cohort study based on 994 patients. Radiotherapy and Oncology, 2011, 100, 108-115.	0.3	62
335	Radiotherapy with curative intent for lung cancer: A continuing success story. Radiotherapy and Oncology, 2011, 101, 237-239.	0.3	7
336	Development and Validation of a Prognostic Model Using Blood Biomarker Information for Prediction of Survival of Non–Small-Cell Lung Cancer Patients Treated With Combined Chemotherapy and Radiation or Radiotherapy Alone (NCT00181519, NCT00573040, and NCT00572325). International Journal of Radiation Oncology Biology Physics, 2011, 81, 360-368.	0.4	61
337	[18F]fluorodeoxyglucose Uptake Patterns in Lung Before Radiotherapy Identify Areas More Susceptible to Radiation-Induced Lung Toxicity in Non-Small-Cell Lung Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2011, 81, 698-705.	0.4	67
338	The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy. Oral Oncology, 2011, 47, 768-774.	0.8	94
339	Nomograms for Predicting Local Recurrence, Distant Metastases, and Overall Survival for Patients With Locally Advanced Rectal Cancer on the Basis of European Randomized Clinical Trials. Journal of Clinical Oncology, 2011, 29, 3163-3172.	0.8	439
340	Optimal gating compared to 3D and 4D PET reconstruction for characterization of lung tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 843-855.	3.3	109
341	Volume or Position Changes of Primary Lung Tumor During (Chemo-)Radiotherapy Cannot Be Used as a Surrogate for Mediastinal Lymph Node Changes: The Case for Optimal Mediastinal Lymph Node Imaging During Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 79, 89-95.	0.4	19
342	Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14620-14625.	3.3	121

#	Article	IF	CITATIONS
343	Impact of Tumor Size and Tracer Uptake Heterogeneity in <sup>18</sup> F-FDG PET and CT Non–Small Cell Lung Cancer Tumor Delineation. Journal of Nuclear Medicine, 2011, 52, 1690-1697.	2.8	126
344	When to Wait for More Evidence? Real Options Analysis in Proton Therapy. Oncologist, 2011, 16, 1752-1761.	1.9	29
345	A Simple but Highly Effective Approach to Evaluate the Prognostic Performance of Gene Expression Signatures. PLoS ONE, 2011, 6, e28320.	1.1	19
346	PET imaging of hypoxia using [18F]HX4: a phase I trial. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1663-1668.	3.3	100
347	The Use of FDG-PET to Target Tumors by Radiotherapy. Strahlentherapie Und Onkologie, 2010, 186, 471-481.	1.0	49
348	Accurate Prediction of Pathological Rectal Tumor Response after Two Weeks of Preoperative Radiochemotherapy Using 18F-Fluorodeoxyglucose-Positron Emission Tomography-Computed Tomography Imaging. International Journal of Radiation Oncology Biology Physics, 2010, 77, 392-399.	0.4	76
349	Patient satisfaction with nurse-led telephone follow-up after curative treatment for breast cancer. BMC Cancer, 2010, 10, 174.	1.1	80
350	Selective Nodal Irradiation on Basis of 18FDG-PET Scans in Limited-Disease Small-Cell Lung Cancer: A Prospective Study. International Journal of Radiation Oncology Biology Physics, 2010, 77, 329-336.	0.4	166
351	Comparison Between Perfusion Computed Tomography and Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 400-408.	0.4	30
352	Accurate Automatic Delineation of Heterogeneous Functional Volumes in Positron Emission Tomography for Oncology Applications. International Journal of Radiation Oncology Biology Physics, 2010, 77, 301-308.	0.4	154
353	Do We Have Enough Evidence to Implement Particle Therapy as Standard Treatment in Lung Cancer? A Systematic Literature Review. Oncologist, 2010, 15, 93-103.	1.9	21
354	Mature Results of an Individualized Radiation Dose Prescription Study Based on Normal Tissue Constraints in Stages I to III Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 1380-1386.	0.8	156
355	Follow-up after treatment for breast cancer: One strategy fits all? An investigation of patient preferences using a discrete choice experiment. Acta Oncol $\tilde{A}^3$ gica, 2010, 49, 328-337.	0.8	53
356	The cost-effectiveness of particle therapy in non-small cell lung cancer: Exploring decision uncertainty and areas for future research. Cancer Treatment Reviews, 2010, 36, 468-476.	3.4	57
357	18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: An economic evaluation. European Journal of Cancer, 2010, 46, 110-119.	1.3	46
358	Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia. Nuclear Medicine and Biology, 2010, 37, 557-564.	0.3	82
359	Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: A meta-analysis. Radiotherapy and Oncology, 2010, 95, 32-40.	0.3	295
360	Dose recalculation in megavoltage cone-beam CT for treatment evaluation: Removal of cupping and truncation artefacts in scans of the thorax and abdomen. Radiotherapy and Oncology, 2010, 94, 359-366.	0.3	20

#	Article	IF	Citations
361	How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiotherapy and Oncology, 2010, 95, 45-53.	0.3	166
362	Tumor perfusion increases during hypofractionated short-course radiotherapy in rectal cancer: Sequential perfusion-CT findings. Radiotherapy and Oncology, 2010, 94, 156-160.	0.3	31
363	3D dose delivery verification using repeated cone-beam imaging and EPID dosimetry for stereotactic body radiotherapy of non-small cell lung cancer. Radiotherapy and Oncology, 2010, 94, 188-194.	0.3	35
364	Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: Sequential FDG-PET-CT findings. Radiotherapy and Oncology, 2010, 94, 151-155.	0.3	42
365	Blood glucose level normalization and accurate timing improves the accuracy of PET-based treatment response predictions in rectal cancer. Radiotherapy and Oncology, 2010, 95, 203-208.	0.3	14
366	A systematic methodology review of phase I radiation dose escalation trials. Radiotherapy and Oncology, 2010, 95, 135-141.	0.3	21
367	FDG for dose painting: A rational choice. Radiotherapy and Oncology, 2010, 97, 163-164.	0.3	37
368	The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: Exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. Radiotherapy and Oncology, 2010, 96, 145-152.	0.3	72
369	Design of and technical challenges involved in a framework for multicentric radiotherapy treatment planning studies. Radiotherapy and Oncology, 2010, 97, 567-571.	0.3	32
370	Effectiveness of surgery and individualized high-dose hyperfractionated accelerated radiotherapy on survival in clinical stage I non-small cell lung cancer. A propensity score matched analysis. Radiotherapy and Oncology, 2010, 97, 413-417.	0.3	7
371	Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients. Radiotherapy and Oncology, 2010, 97, 455-461.	0.3	70
372	Health-related quality of life in patients surviving non-small cell lung cancer. Thorax, 2010, 65, 903-907.	2.7	77
373	Prediction of residual metabolic activity after treatment in NSCLC patients. Acta Oncol $\tilde{A}^3$ gica, 2010, 49, 1033-1039.	0.8	19
374	Carbonic anhydrase inhibitors: Gd(iii) complexes of DOTA- and TETA-sulfonamide conjugates targeting the tumor associated carbonic anhydrase isozymes IX and XII. New Journal of Chemistry, 2010, 34, 2139.	1.4	5
375	FDG-PET-CT for staging of high-risk breast cancer patients reduces the number of further examinations: A pilot study. Acta Oncol $\tilde{A}^3$ gica, 2010, 49, 185-191.	0.8	17
376	The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. Journal of Clinical Investigation, 2010, 120, 127-141.	3.9	675
377	Hypoxia-induced Expression of Carbonic Anhydrase 9 Is Dependent on the Unfolded Protein Response. Journal of Biological Chemistry, 2009, 284, 24204-24212.	1.6	57
378	Intra-voxel heterogeneity influences the dose prescription for dose-painting with radiotherapy: a modelling study. Physics in Medicine and Biology, 2009, 54, 2179-2196.	1.6	55

#	Article	IF	Citations
379	Disparity Between In Vivo EGFR Expression and <sup>89</sup> Zr-Labeled Cetuximab Uptake Assessed with PET. Journal of Nuclear Medicine, 2009, 50, 123-131.	2.8	180
380	Evaluation of nonrigid registration models for interfraction dose accumulation in radiotherapy. Medical Physics, 2009, 36, 4268-4276.	1.6	73
381	Phased Versus Midventilation Attenuation-Corrected Respiration-Correlated PET for Patients with Non-Small Cell Lung Cancer. Journal of Nuclear Medicine Technology, 2009, 37, 208-214.	0.4	9
382	Tumor Delineation Based on Time–Activity Curve Differences Assessed With Dynamic Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in Rectal Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2009, 73, 456-465.	0.4	31
383	Development and External Validation of Prognostic Model for 2-Year Survival of Non–Small-Cell Lung Cancer Patients Treated With Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 74, 355-362.	0.4	82
384	3D In Vivo Dosimetry Using Megavoltage Cone-Beam CT and EPID Dosimetry. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1580-1587.	0.4	71
385	Inhibition of 4E-BP1 Sensitizes U87 Glioblastoma Xenograft Tumors to Irradiation by Decreasing Hypoxia Tolerance. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1219-1227.	0.4	36
386	Follow-up with 18FDG-PET–CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: A prospective study. European Journal of Cancer, 2009, 45, 588-595.	1.3	50
387	Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 1-39.	2.5	167
388	Responsiveness of the EQ-5D in breast cancer patients in their first year after treatment. Health and Quality of Life Outcomes, 2009, $7, 11$ .	1.0	43
389	Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer. Radiotherapy and Oncology, 2009, 91, 353-359.	0.3	35
390	The importance of patient characteristics for the prediction of radiation-induced lung toxicity. Radiotherapy and Oncology, 2009, 91, 421-426.	0.3	85
391	Increased 18F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): A prospective pilot study. Radiotherapy and Oncology, 2009, 91, 415-420.	0.3	64
392	In response to the "Letter to the Editor―by Borst et al.: Dyspnea evaluation after high-dose radiotherapy in patients with NSCLC. Radiotherapy and Oncology, 2009, 91, 461-462.	0.3	0
393	High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL. Radiotherapy and Oncology, 2009, 91, 443-448.	0.3	42
394	Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): An exploratory clinical study. Radiotherapy and Oncology, 2009, 91, 393-398.	0.3	53
395	Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan. Radiotherapy and Oncology, 2009, 91, 386-392.	0.3	340
396	Can we optimize chemo-radiation and surgery in locally advanced stage III non-small cell lung cancer based on evidence from randomized clinical trials? A hypothesis-generating study. Radiotherapy and Oncology, 2009, 93, 389-395.	0.3	14

#	Article	IF	Citations
397	The use of a comprehensive tumour xenograft dataset to validate gene signatures relevant for radiation response. Radiotherapy and Oncology, 2009, 92, 417-422.	0.3	18
398	The deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironment. Radiotherapy and Oncology, 2009, 92, 399-404.	0.3	23
399	Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiotherapy and Oncology, 2009, 92, 423-428.	0.3	185
400	Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells. Radiotherapy and Oncology, 2009, 92, 393-398.	0.3	36
401	Autophagy is required during cycling hypoxia to lower production of reactive oxygen species. Radiotherapy and Oncology, 2009, 92, 411-416.	0.3	130
402	Survival Prediction in Lung Cancer Treated with Radiotherapy: Bayesian Networks vs. Support Vector Machines in Handling Missing Data. , 2009, , .		11
403	The mTOR target 4Eâ€BP1 contributes to differential protein expression during normoxia and hypoxia through changes in mRNA translation efficiency. Proteomics, 2008, 8, 1019-1028.	1.3	45
404	Tumor Volume Combined With Number of Positive Lymph Node Stations Is a More Important Prognostic Factor Than TNM Stage for Survival of Non–Small-Cell Lung Cancer Patients Treated With (Chemo)radiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1039-1044.	0.4	101
405	Time Trends in Nodal Volumes and Motion During Radiotherapy for Patients With Stage III Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 71, 139-144.	0.4	27
406	HI-CHART: A Phase I/II Study on the Feasibility of High-Dose Continuous Hyperfractionated Accelerated Radiotherapy in Patients With Inoperable Non–Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 71, 132-138.	0.4	41
407	Radiation Dose Prescription for Non–Small-Cell Lung Cancer According to Normal Tissue Dose Constraints: An In Silico Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1103-1110.	0.4	66
408	Stability of 18F-Deoxyglucose Uptake Locations Within Tumor During Radiotherapy for NSCLC: A Prospective Study. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1402-1407.	0.4	81
409	Individualized Radical Radiotherapy of Non–Small-Cell Lung Cancer Based on Normal Tissue Dose Constraints: A Feasibility Study. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1394-1401.	0.4	57
410	Particle therapy in lung cancer: Where do we stand?. Cancer Treatment Reviews, 2008, 34, 259-267.	3.4	22
411	The next step in patient-specific QA: 3D dose verification of conformal and intensity-modulated RT based on EPID dosimetry and Monte Carlo dose calculations. Radiotherapy and Oncology, 2008, 86, 86-92.	0.3	83
412	The integration of PET-CT scans from different hospitals into radiotherapy treatment planning. Radiotherapy and Oncology, 2008, 87, 142-146.	0.3	52
413	Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: A feasibility study. Radiotherapy and Oncology, 2008, 87, 55-58.	0.3	66
414	18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: A planning study. Radiotherapy and Oncology, 2008, 87, 49-54.	0.3	82

#	Article	IF	Citations
415	Transition from a simple to a more advanced dose calculation algorithm for radiotherapy of non-small cell lung cancer (NSCLC): Implications for clinical implementation in an individualized dose-escalation protocol. Radiotherapy and Oncology, 2008, 88, 326-334.	0.3	30
416	A literature review of electronic portal imaging for radiotherapy dosimetry. Radiotherapy and Oncology, 2008, 88, 289-309.	0.3	384
417	Why determine only the total prostate-specific antigen, if the free-to-total ratio contains the information?. Annals of Clinical Biochemistry, 2008, 45, 270-274.	0.8	0
418	Calibration of megavoltage coneâ€beam CT for radiotherapy dose calculations: Correction of cupping artifacts and conversion of CT numbers to electron density. Medical Physics, 2008, 35, 849-865.	1.6	29
419	Treatment verification in the presence of inhomogeneities using EPIDâ€based threeâ€dimensional dose reconstruction. Medical Physics, 2007, 34, 2816-2826.	1.6	39
420	P3-046: Personalized High-Dose Continuous Hyperfractionated Accelerated Radiotherapy (HI-CHART) of non-small cell lung cancer (NSCLC) based on normal tissue constraints: a prospective clinical trial. Journal of Thoracic Oncology, 2007, 2, S626.	0.5	1
421	The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor- $\hat{\Pi}$ and GLUT-1 in non-small cell lung cancer. European Journal of Cancer, 2007, 43, 1392-1398.	1.3	188
422	Timing of chest radiotherapy in patients with limited stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials. Cancer Treatment Reviews, 2007, 33, 461-473.	3.4	133
423	Formation of lysine 63-linked poly-ubiquitin chains protects human lung cells against benzo[a]pyrene-diol-epoxide-induced mutagenicity. DNA Repair, 2007, 6, 852-862.	1.3	11
424	Prone breast irradiation for pendulous breasts. Radiotherapy and Oncology, 2007, 82, 337-340.	0.3	55
425	Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: Possible role for thrombosis. Radiotherapy and Oncology, 2007, 82, 96-104.	0.3	43
426	Radiation-induced bullous pemphigoid: A systematic review of an unusual radiation side effect. Radiotherapy and Oncology, 2007, 82, 5-9.	0.3	63
427	Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiotherapy and Oncology, 2007, 82, 145-152.	0.3	101
428	Routine individualised patient dosimetry using electronic portal imaging devices. Radiotherapy and Oncology, 2007, 83, 65-75.	0.3	91
429	Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiotherapy and Oncology, 2007, 83, 367-373.	0.3	157
430	Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance. Radiotherapy and Oncology, 2007, 83, 333-339.	0.3	46
431	Regulation of Cited2 expression provides a functional link between translational and transcriptional responses during hypoxia. Radiotherapy and Oncology, 2007, 83, 346-352.	0.3	24
432	Proteomic analysis of gene expression following hypoxia and reoxygenation reveals proteins involved in the recovery from endoplasmic reticulum and oxidative stress. Radiotherapy and Oncology, 2007, 83, 340-345.	0.3	21

#	Article	IF	Citations
433	Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII. Radiotherapy and Oncology, 2007, 83, 326-332.	0.3	28
434	Phosphorylation of eIF2 $\hat{l}\pm$ is required for mRNA translation inhibition and survival during moderate hypoxia. Radiotherapy and Oncology, 2007, 83, 353-361.	0.3	54
435	Impact of supervised gene signatures of early hypoxia on patient survival. Radiotherapy and Oncology, 2007, 83, 374-382.	0.3	80
436	Tumour delineation and cumulative dose computation in radiotherapy based on deformable registration of respiratory correlated CT images of lung cancer patients. Radiotherapy and Oncology, 2007, 85, 232-238.	0.3	64
437	PET-CT–Based Auto-Contouring in Non–Small-Cell Lung Cancer Correlates With Pathology and Reduces Interobserver Variability in the Delineation of the Primary Tumor and Involved Nodal Volumes. International Journal of Radiation Oncology Biology Physics, 2007, 68, 771-778.	0.4	274
438	Total Body Irradiation, Toward Optimal Individual Delivery: Dose Evaluation With Metal Oxide Field Effect Transistors, Thermoluminescence Detectors, and a Treatment Planning System. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1297-1304.	0.4	39
439	Improving the quality and efficiency of follow-up after curative treatment for breast cancer $\hat{a} \in \text{``}$ rationale and study design of the MaCare trial. BMC Cancer, 2007, 7, 1.	1.1	78
440	Biomarkers for radiation-induced small bowel epithelial damage: An emerging role for plasma Citrulline. World Journal of Gastroenterology, 2007, 13, 3033.	1.4	95
441	Palliative chest irradiation in sitting position in patients with bulky advanced lung cancer. Radiotherapy and Oncology, 2006, 79, 285-287.	0.3	10
442	Clinical implementation of MOSFET detectors for dosimetry in electron beams. Radiotherapy and Oncology, 2006, 80, 288-295.	0.3	24
443	Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: A phase II trial. Radiotherapy and Oncology, 2006, 80, 307-312.	0.3	123
444	An "in silico―clinical trial comparing free breathing, slow and respiration correlated computed tomography in lung cancer patients. Radiotherapy and Oncology, 2006, 81, 73-80.	0.3	28
445	The current status of FDG–PET in tumour volume definition in radiotherapy treatment planning. Cancer Treatment Reviews, 2006, 32, 245-260.	3.4	153
446	Psychometric properties of the revised Piper Fatigue Scale in Dutch cancer patients were satisfactory. Journal of Clinical Epidemiology, 2006, 59, 642-649.	2.4	31
447	Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO Journal, 2006, 25, 1114-1125.	3.5	328
448	Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: A prospective clinical study. International Journal of Radiation Oncology Biology Physics, 2006, 66, 748-753.	0.4	105
449	Quality Assurance in the EORTC Randomized Trial 22922/10925 Investigating the Role of Irradiation of the Internal Mammary and Medial Supraclavicular Lymph Node Chain Works. Strahlentherapie Und Onkologie, 2006, 182, 576-582.	1.0	35
450	Development of a flexible and potent hypoxia-inducible promoter for tumor-targeted gene expression in attenuated s <i>almonella</i> . Cancer Biology and Therapy, 2006, 5, 1120-1128.	1.5	81

#	Article	IF	Citations
451	Lysine 63-Polyubiquitination Guards against Translesion Synthesis–Induced Mutations. PLoS Genetics, 2006, 2, e116.	1.5	109
452	A Monte Carlo based three-dimensional dose reconstruction method derived from portal dose images. Medical Physics, 2006, 33, 2426-2434.	1.6	63
453	Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 1057-1063.	0.8	301
454	Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non–small-cell lung cancer: A modeling study. International Journal of Radiation Oncology Biology Physics, 2005, 61, 649-655.	0.4	151
455	Selective mediastinal node irradiation based on FDG-PET scan data in patients with non–small-cell lung cancer: A prospective clinical study. International Journal of Radiation Oncology Biology Physics, 2005, 62, 988-994.	0.4	202
456	Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1309-1315.	0.4	128
457	Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration. Cancer, 2005, 103, 191-199.	2.0	145
458	Secretory production of biologically active rat interleukin-2 byClostridium acetobutylicumDSM792 as a tool for anti-tumor treatment. FEMS Microbiology Letters, 2005, 246, 67-73.	0.7	69
459	Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: A planning study. Radiotherapy and Oncology, 2005, 77, 5-10.	0.3	135
460	The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiotherapy and Oncology, 2005, 76, 177-186.	0.3	105
461	Health related quality of life assessment instruments: A prospective study on preference and acceptability among cancer patients referred for radiotherapy. European Journal of Cancer, 2005, 41, 2250-2256.	1.3	11
462	Bacterial Systems for Tumor-Specific Gene Therapy. , 2005, , 393-404.		O
463	Plasma citrulline concentration: A surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients. International Journal of Radiation Oncology Biology Physics, 2004, 60, 275-285.	0.4	113
464	Targeting hypoxia tolerance in cancer. Drug Resistance Updates, 2004, 7, 25-40.	6.5	81
465	Early improvements in vision after fractionated stereotactic radiotherapy for primary optic nerve sheath meningioma. Radiotherapy and Oncology, 2004, 72, 169-174.	0.3	106
466	Dose–response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiotherapy and Oncology, 2004, 73, 297-306.	0.3	85
467	Early versus late chest radiotherapy in patients with limited-stage small cell lung cancer. The Cochrane Library, 2004, , CD004700.	1.5	49
468	Modulation of cell death in the tumor microenvironment. Seminars in Radiation Oncology, 2003, 13, 31-41.	1.0	91

#	Article	IF	CITATIONS
469	Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. International Journal of Cancer, 2003, 105, 20-25.	2.3	46
470	Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1351-1356.	0.4	169
471	Citrulline: A physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1067-1074.	0.4	120
472	Clinical dosimetry with MOSFET dosimeters to determine the dose along the field junction in a split beam technique. Radiotherapy and Oncology, 2003, 67, 351-357.	0.3	30
473	The importance of pre-treatment haemoglobin level in inoperablenon-small cell lung carcinoma treated with radical radiotherapy. Radiotherapy and Oncology, 2003, 67, 321-325.	0.3	30
474	Clostridium-Mediated Transfer of Therapeutic Proteins to Solid Tumors. , 2003, , 527-546.		1
475	Preservation of parotid function with uncomplicated conformal radiotherapy. Radiotherapy and Oncology, 2002, 63, 203-211.	0.3	115
476	Does sucralfate reduce early side effects of pelvic radiation? A double-blind randomized trial. Radiotherapy and Oncology, 2002, 65, 105-108.	0.3	19
477	In vivo animal functional MRI: Improved image quality with a body-adapted mold. Journal of Magnetic Resonance Imaging, 2002, 16, 224-227.	1.9	14
478	An experimental evaluation of three preoperative radiation regimens for resectable rectal cancer. Annals of Surgical Oncology, 2002, 9, 292-297.	0.7	6
479	Preservation of parotid function with uncomplicated conformal radiotherapy. Radiotherapy and Oncology, 2002, 63, 203-11.	0.3	24
480	Optimization of tumor-targeted gene delivery by engineered attenuated Salmonella typhimurium. Anticancer Research, 2002, 22, 3261-6.	0.5	27
481	In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. International Journal of Radiation Oncology Biology Physics, 2001, 49, 443-450.	0.4	83
482	BOLD contrast fMRI of whole rodent tumour during air or carbogen breathing using echo-planar imaging at 1.5 T. European Radiology, 2001, 11, 2332-2340.	2.3	31
483	Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunology and Medical Microbiology, 2001, 30, 37-41.	2.7	43
484	Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Therapy, 2001, 8, 294-297.	2.2	97
485	Effect of TNP-470 (AGM-1470) on the Growth of Rat Rhabdomyosarcoma Tumors of Different Sizes. Cancer Investigation, 2001, 19, 35-40.	0.6	11
486	Tumoural perfusion as measured by dynamic computed tomography in head and neck carcinoma. Radiotherapy and Oncology, 1999, 53, 105-111.	0.3	75

#	Article	IF	CITATIONS
487	Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiotherapy and Oncology, 1998, 47, 149-153.	0.3	75
488	Tumour Size in Cancer of the Cervix. Acta Oncol $\tilde{A}^3$ gica, 1998, 37, 729-734.	0.8	14
489	Is pulsed dose rate more damaging to spinal cord of rats than continuous low dose rate?. Radiotherapy and Oncology, 1997, 45, 39-47.	0.3	20
490	Non-invasive tumour perfusion measurement by dynamic CT: preliminary results. Radiotherapy and Oncology, 1997, 44, 159-162.	0.3	48
491	Potential role for low dose limited-field radiation therapy (2 $ ilde{A}$ — 2 grays) in advanced low-grade non-Hodgkin's lymphomas. Hematological Oncology, 1994, 12, 1-8.	0.8	78
492	A comparison of early effects with two dose rates in brachytherapy of cervix carcinoma in a prospective randomised trial. European Journal of Cancer, 1994, 30, 312-320.	1.3	17
493	Oxygenation of head and neck tumors. Cancer, 1993, 71, 2319-2325.	2.0	164
494	Diagnosis of Idiopathic Pulmonary Fibrosis in High-Resolution Computed Tomography Scans Using a Combination of Handcrafted Radiomics and Deep Learning. Frontiers in Medicine, 0, 9, .	1.2	8
495	Predicting Adverse Radiation Effects in Brain Tumors After Stereotactic Radiotherapy With Deep Learning and Handcrafted Radiomics. Frontiers in Oncology, 0, 12, .	1.3	3